RYTM News and Press, Rhythm Pharmaceuticals Inc. From 10/10/22

Summary Today, we circle back on Rhythm Therapeutics for the first time in over a year and a half. The company continues to advance its main asset Imcivree across multiple indications and recently addressed its near-term financing needs. The stock is up some 125% in 2022 on th...

BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathw...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

-- Book developed in collaboration with the Bardet-Biedl Syndrome Foundation -- -- BBS Global Day on Sept. 24 coordinated by BBS International -- BOSTON, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical comp...

BOSTON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocort...

-- CARE-BBS multi-country survey of 242 caregivers of individuals with Bardet-Biedl syndrome (BBS) provides extensive details on impact of hyperphagia and obesity -- -- New analyses of Phase 3 data showed setmelanotide achieved substantial weight loss benefit in adolescent and ped...

Rhythm Pharmaceuticals ( NASDAQ: RYTM ) shares are down 11.7% after-hours after the firm prices its public offering of 4.8M shares of its common stock at a public offering price of $26.00/share. All of the shares are being offered by Rhythm. Underwriters are grante...

Rhythm Pharmaceuticals ( NASDAQ: RYTM ) on Wednesday announced a proposed public offering of $100M of its shares. Shares of RYTM, which ended 24.3% higher on Wednesday, dropped ~12% after hours. RYTM intends to grant underwriters a 30-day option to buy up to an...

Rhythm Pharmaceuticals ( NASDAQ: RYTM ) on Tuesday said the European Commission had expanded the marketing approval for its Imcivree drug to include the treatment of obesity and control of hunger associated with Bardet-Biedl syndrome (BBS). BBS is a genetic condition t...

-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) -- -- EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue Interest Agreement with HealthCare Royalty -- -- Health Canada grants Priority Review sta...